Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 14/20 | 0.45 |
| ▸ | KCNK9 | Q9NPC2 | 14/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20587818 | 0.85 | ALDH1A1 (0.68) | ALDH1A1RAB9AKDM4ESMN1; SMN2GLA | |
| SCHEMBL15114823 | 0.84 | GAA (0.56) | ALDH1A1RAB9AKDM4ESMN1; SMN2GLA | |
| SCHEMBL22001925 | 0.83 | ALDH1A1 (0.50) | ALDH1A1RAB9AKDM4ESMN1; SMN2GLA | |
| SCHEMBL18952249 | 0.79 | NPC1 (0.73) | ALDH1A1RAB9AKDM4ESMN1; SMN2GAA | |
| SCHEMBL30417973 | 0.72 | KCNK3 (0.69) | KCNK3KCNK9 | |
| SCHEMBL29935956 | 0.71 | KDM4E (0.49) | ALDH1A1RAB9AKDM4ESMN1; SMN2GLA | |
| SCHEMBL25238913 | 0.71 | KCNK3 (0.69) | KCNK3KCNK9 | |
| SCHEMBL20588935 | 0.71 | KCNK3 (0.68) | KCNK3KCNK9 | |
| SCHEMBL14881844 | 0.70 | GPBAR1 (0.80) | ALDH1A1RAB9AKDM4ESMN1; SMN2GLA | |
| SCHEMBL30359090 | 0.70 | KCNK3 (0.64) | KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154175-A1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | disclosed |
| US-12180227-B2 | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | BAYER AKTIENGESELLSCHAFT (DE) | 2024-12-31 | — | — | US | disclosed |
| CN-115554300-B | Diazabicyclo-substituted imidazopyrimidines and their use for the treatment of respiratory disorders | 拜耳股份公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-3638675-B1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | BAYER AG (DE) | 2024-04-17 | — | — | EP | disclosed |
| CN-116057057-A | Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea | 拜耳公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115583959-A | Diazabicyclo-substituted imidazopyrimidines and their use for the treatment of respiratory disorders | 拜耳股份公司 | 2023-01-10 | — | — | CN | disclosed |
| CN-115554300-A | Diazabicyclo-substituted imidazopyrimidines and their use for the treatment of respiratory disorders | 拜耳股份公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115554299-A | Diazabicyclo-substituted imidazopyrimidines and their use for the treatment of respiratory disorders | 拜耳股份公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-110719911-B | Diazabicyclo-substituted imidazopyrimidines and their use for the treatment of respiratory disorders | 拜耳股份公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20220017540-A1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-20 | — | — | US | disclosed |
| US-20220017540-A1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-20 | — | — | US | disclosed |
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| EP-3638676-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2020-04-22 | — | — | EP | disclosed |
| US-20200109155-A1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-09 | — | — | US | disclosed |
| WO-2018228909-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BET1, HRH1, GRIN1 | ALDH1A1 1483/4885RAB9A 4077/4885KDM4E 1380/4885 |
| US-12180227-B2 | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | HIF1AN, QDPR, DHPS | ALDH1A1 233/4885RAB9A 4265/4885KDM4E 2307/4885 |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | GRIN1, BET1, HRH1 | ALDH1A1 1542/4885RAB9A 4140/4885KDM4E 1415/4885 |
| US-20250154175-A1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | HIF1AN, QDPR, HNMT | ALDH1A1 645/4885RAB9A 4465/4885KDM4E 2052/4885 |
| US-20220017540-A1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | HIF1AN, QDPR, HNMT | ALDH1A1 645/4885RAB9A 4465/4885KDM4E 2052/4885 |
| US-20200109155-A1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | HIF1AN, QDPR, HNMT | ALDH1A1 645/4885RAB9A 4465/4885KDM4E 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.